Please select the eligibility criteria that correspond to the clinical trial below.
Title: Elective Blastocyst Vitrification for Endometrial Receptivity Enhancement in High-responder Patients Undergoing in Vitro Fertilisation/Intracytoplasmatic Sperm Injection (IVF/ICSI)
Brief Summary: A randomised controlled open-label clinical trial to compare the clinical pregnancy rates between fresh embryo transfer and elective all-embryo vitrification with thawing and transfer in a subsequent cycle in high-responders


Options:
A: Inclusion Criteria:

* 1st, 2nd or 3rd cycle of PGD in which embryo transfer was performed
* Indications for PGD: monogenic indications and X-linked disorders with a 25-50% risk of transmission and that are not associated with reduced ovarian response
* Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.
* Regular menstrual cycles of 21-35 days, presumed to be ovulatory.

Exclusion Criteria:

* POLYCYSTIC OVARIAN SYNDROME (Rotterdam criteria \*)

  \* At least two of the following three features: (i) Oligo- and/or anovulation (ii) Clinical and/or biochemical signs of hyperandrogenism (iii) Polycystic ovaries and exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting tumours, Cushing's syndrome)
* Poor responders (Bologna criteria \*\*)

  \* \* At least two of the following three features: (i) Advanced maternal age (≥40 years) or any other risk factor for poor ovarian response (POR); (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. antral follicle count (AFC) 5-7 follicles, or anti-Mullerian hormone (AMH) 0.5-1.1 ng/ml).
* Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)
* anticipated high response: AMH \>5.0 ng/ml or AFC \>20
* Endometriosis ≥ grade 3
* Age \> 40 years and 364 days
B: Inclusion Criteria:

* First or second IVF/ICSI cycle
* High response to ovarian stimulation (defined as presence of ≥18 follicles of ≥11 mm on the day of GnRH triggering)
* GnRH antagonist down-regulation
* Signed informed consent
* Patients can be included only once in the trial
* Planned replacement of 1 or 2 blastocysts

Exclusion Criteria:

* Other known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis)
* Oocyte/embryos donation acceptors
* Embryos planned to undergo preimplantation genetic diagnosis/screening
* Body mass index ≥35 or ≤18
* Women who have previously enrolled in the trial
* Those unable to comprehend the investigational nature of the proposed study
C: Inclusion Criteria (pre-stimulation):

* Age up to 42 years

Exclusion Criteria (pre-stimulation):

* MESA and TESE patients
* At least one partner carrier of a chromosomal abnormality
* Egg donor cycle (sperm donor is acceptable)
* Gender selection cycles
* Thaw cycles
* Any patient who cannot have a fresh embryo transfer
* FSH above 12 or AMH less than 1
D: Inclusion Criteria:

* Women under 42 years of age
* Presence of at least 3 embryos suitable to freeze on day 2 or 3 following fertilisation based on the centre's criteria
* Written informed consent

Exclusion Criteria:

* Women using donor eggs/donor sperm
* Women undergoing preimplantation genetic diagnosis
* Women with abnormal uterine cavity shown on hysterosalpingogram or saline infusion sonogram
* Women with hydrosalpinges shown on scanning and not corrected treated
* Women with excessive ovarian response at risk of ovarian hyperstimulation where elective freeze is already planned
* Women with serum progesterone level on day of human chorionic gonadotrophin\>1.5ng/ml or 5 nmol/L
* Women whose embryos have not survived freeze-thawing in the past
* Fresh transfer is planned e.g. patients with endometriosis or adenomyosis who have received prolonged downregulation
* Only frozen transfer is planned e.g. patients receiving ovarian stimulation regimens which may have adverse impacts on the endometrium

Answer: B